Physician profile
Bruce H Cohen
NPI 1053355107
$10,778.58
in general payments reported to CMS, 2019-2025
28 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,969 · 2020: $1,000 · 2021: $1,221 · 2022: $678 · 2023: $1,613 · 2024: $1,392 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,911.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,729.35 | 2019-2022 | |
| Allergan, INC. | $1,220.53 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,126.14 | 2019-2021 | |
| Alcon Vision LLC | $1,083.55 | 2020-2025 | Hydrus Microstent, Tryptyr, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $784.26 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Glaukos Corporation | $681.91 | 2023-2024 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Bausch & Lomb Americas INC. | $514.98 | 2022-2025 | Miebo, Xiidra, Infuse |
| Sun Pharmaceutical Industries INC. | $447.07 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $445.76 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $347.03 | 2019-2024 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $280.37 | 2024-2025 | Veracity Surgical |
| Mallinckrodt Hospital Products INC. | $258.79 | 2023-2025 | Acthar |
| Rxsight INC | $197.06 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Johnson & Johnson Vision Care, INC. | $190.42 | 2022-2025 | |
| Oyster Point Pharma, INC. | $163.91 | 2022-2024 | Tyrvaya |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $152.99 | 2024 | Omni Surgical System |
| Harrow Eye, LLC | $133.86 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $132.11 | 2019-2021 | |
| Ivantis, INC | $131.42 | 2020 | |
| Amgen INC. | $124.69 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $122.63 | 2019 | |
| Dompe US, INC. | $121.80 | 2023 | Oxervate |
| Thea Pharma INC. | $121.78 | 2023-2025 | Iyuzeh |
| Coopervision INC. | $106.50 | 2025 | Misight Contact Lens |
| Biotissue Holdings INC. | $64.44 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $57.77 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $18.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.